Cumberland Pharmaceuticals (CPIX) Income from Non-Controlling Interests (2010 - 2026)
Cumberland Pharmaceuticals' (CPIX) quarterly Income from Non-Controlling Interests came in at $2588.0 in Q1 2026, up 129.13% year-on-year from $1129.5 in Q1 2025, and up 115.27% quarter-over-quarter from -$16950.0 in Q4 2025.
Cumberland Pharmaceuticals (CPIX) Income from Non-Controlling Interests (2010 - 2026) Analysis & Trends
Cumberland Pharmaceuticals has disclosed Income from Non-Controlling Interests across 17 years of filings, most recently posting $2588.0 for Q1 2026.
- Income from Non-Controlling Interests for Q1 2026 came in at $2588.0, up 129.13% year-over-year; the trailing twelve-month figure through Mar 2026 was -$17111.0 (down 2.95% YoY), and the FY2025 annual result was -$28583.0, down 179.28% from the prior year.
- Income from Non-Controlling Interests came in at $2588.0 for Q1 2026 at Cumberland Pharmaceuticals, up from -$16950.0 in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $43791.0 in Q1 2024 to a low of -$29046.0 in Q2 2022.
- The 5-year median for Income from Non-Controlling Interests is -$10046.0 (2023), against an average of -$7128.5.
- Across the five-year window, Income from Non-Controlling Interests jumped 320.08% in 2024 and slumped 878.59% in 2025, its largest moves.
- Cumberland Pharmaceuticals' Income from Non-Controlling Interests stood at -$18985.0 in 2022, then jumped by 60.07% to -$7581.0 in 2023, then jumped by 128.72% to $2177.0 in 2024, then plunged by 878.59% to -$16950.0 in 2025, then jumped by 115.27% to $2588.0 in 2026.
- The last three Income from Non-Controlling Interests figures came in at $2588.0 (Q1 2026), -$16950.0 (Q4 2025), and -$8282.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | - |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | - |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | - |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 22.56 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | - |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | - |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | - |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | - |
| 10 | Cumberland Pharmaceuticals | 86.62 Mn | 75.28 Mn | 7.20 Mn | 2,588.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2,588.00 |
| Dec 31, 2025 | -16,950.00 |
| Sep 30, 2025 | -8,282.00 |
| Jun 30, 2025 | 5,533.00 |
| Mar 31, 2025 | -8,884.00 |
| Dec 31, 2024 | 2,177.00 |
| Sep 30, 2024 | 7,112.00 |
| Jun 30, 2024 | -17,025.00 |
| Mar 31, 2024 | 43,791.00 |
| Dec 31, 2023 | -7,581.00 |
| Sep 30, 2023 | -13,921.00 |
| Jun 30, 2023 | -10,046.00 |
| Mar 31, 2023 | -19,898.00 |
| Dec 31, 2022 | -18,985.00 |
| Sep 30, 2022 | -14,587.00 |
| Jun 30, 2022 | -29,046.00 |
| Mar 31, 2022 | -17,180.00 |
| Dec 31, 2021 | -36,561.00 |
| Sep 30, 2021 | -31,415.00 |
| Jun 30, 2021 | -5,069.00 |